Legend Biotech – Talk Bio

J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment

7 months ago talkbio0Tagged Benefit, CAR-T, CARTITUDE-4, Carvykti, Continuance of life, Johnson & Johnson, Legend Biotech, Multiple Myeloma, second-line

Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment

Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events

8 months ago talkbio0Tagged Adverse event, amgen, Antibodies, Bispecific, CAR-T, Carvykti, China, Curon Biopharmaceutical, Evaluation procedure, File (record), Legend Biotech, Merck, United States Food and Drug Administration

Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti

J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment

10 months ago talkbio0Tagged Approved, BCMA-targeted therapy, CARTITUDE-4, Carvykti, Legend, Legend Biotech, Multiple Myeloma, Phase III, United States Food and Drug Administration

Carvykti, Multiple Myeloma, Phase III, CARTITUDE-4, FDA Approval, BCMA-Targeted Therapy, Johnson & Johnson, Legend Biotech